We investigated the role of stress-activated p38 MAP kinase (p38/SAPK-2) signaling in delayed preconditioning of the heart. Adult male out-bred ICR mice were treated with p38 activator, anisomycin (0.1 mg/kg IP), or vehicle (5% DMSO). Twenty-four hours later, hearts were perfused in Langendorff mode and subjected to 30 minutes of ischemia and 30 minutes of reperfusion. Improvement in postischemic recovery of end-diastolic pressure and reduction in infarct size was observed, which was abolished by SB203580, a specific p38 inhibitor, and pyrrolidinediethyldithiocarbamate (PDTC), the NF-B inhibitor, but not by PD 98059, a specific inhibitor for MEK1 or 2. Transient increase in p38 phosphorylation was observed 15 minutes after anisomycin treatment which subsided by 30 minutes. Electrophoretic mobility shift assay demonstrated rapid activation of NF-B DNA binding with anisomycin, peaking at 30 minutes. Western blot confirmed the accumulation of p50 and p65 in nuclear extracts after anisomycin treatment. Anisomycin-induced NF-B DNA binding activity was inhibited by SB203580 and PDTC. Expression of inducible nitric oxide synthase (iNOS) mRNA, protein, and nitric oxide (NO) synthesis were enhanced in anisomycin-treated mice. SB203580 and PDTC blocked the increased expression of iNOS and increase in synthesis of NO. Selective iNOS inhibitor S-methylisothiourea abolished the protective effect of anisomycin. Furthermore, postischemic cardioprotective effect of anisomycin was absent in mice with targeted ablation of iNOS gene but not in the wild-type B6.129 mice. For the first time, these results suggest that direct pharmacological activation of p38 triggers delayed preconditioning by signaling mechanism involving NF-B activation and synthesis of NO from iNOS. (Circ Res. 2001;89:915-922.) Key Words: anisomycin Ⅲ p38 mitogen-activated protein kinase Ⅲ nuclear factor-B Ⅲ nitric oxide Ⅲ ischemia Original
B rief ischemia before a second sustained ischemia decreases myocardial infarction. 1 This cardioprotective phenomenon, known as ischemic preconditioning (IPC), has been classified into two temporally distinct phases: an early or acute phase that wanes within 2 to 4 hours, and a late phase of IPC that becomes manifest 24 to 72 hours later. 2, 3 Recent studies suggest an important role of MAP kinase family, particularly p38, in the early phase of IPC, 4 but the results have been controversial. 5 It has been shown that p38 and MAPKAP kinase-2 are strongly activated by ischemia in the perfused rat heart. 6 Direct activation of p38 by anisomycin mimicked IPC in the hearts, 7,8 myocytes, 9 and hepatocytes against hypoxic insults. 10 However, the role of p38 in the late preconditioning has not been investigated thoroughly. Dana et al 11 showed that late preconditioning induced by transient activation of adenosine A 1 receptor with 2-chloro-N 6cyclopentyladenosine (CCPA) was accompanied by significant rise in p38 activity. We further demonstrated that CCPA-induced delayed protection was abolished by p38 inhibitor SB203580 in the mouse heart, 12 suggesting an essential role of p38 in protection. Also, recently we showed that heat stress-induced delayed protection was mediated by MAP kinases. 13 However, we should consider the fact that IPC or possibly heat shock may trigger a number of additional signaling pathways, including activation of G-proteincoupled receptors, protein kinase C, and MAP kinases such as p44/42, p46/54 (JNK 1/2), and MAPKAP kinase-2. 6,14 -17 These signaling molecules can potentially induce the synthesis of effector protein(s) of cardioprotection either individually or in concert. Therefore, it is difficult to elucidate the direct role of a specific MAP kinase such as p38 in cardioprotection using an IPC model. Accordingly, a desirable approach would be to use an agent/drug that selectively targets the signaling molecule of interest. Furthermore, the downstream signaling mechanism(s) by which p38 phosphorylation transduces the stress signal at the level of transcription or posttranslation leading to the development of late preconditioning is not fully understood. Recent studies suggest that IPC triggered activation and translocation of nuclear transcription factor B (NF-B) in the heart, 18 which has been shown to be essential in the development of delayed preconditioning in vivo. 19 In addition, iNOS has been implicated unequivocally in the late phase of cardioprotection induced by pharmacological agents 20, [21] [22] [23] or IPC. 24, 25 Accordingly, we hypothesized that direct activation of p38 would trigger delayed preconditioning via downstream activation of NF-B and synthesis of iNOS. In the present study, we used anisomycin, an antibiotic isolated from Streptomyces griseolus that inhibits protein synthesis in eukaryotic ribosomes. 26 It inhibits translation by binding to 60S ribosomal subunits and blocking peptide bond formation. More recently, anisomycin has been shown to activate the stress-activated p38 MAP kinase cascades and SAPK/JNK, which makes it a useful tool to study the biological role of phosphorylation pathways in mammalian cells. [27] [28] [29] The goals of the present study were as follows: (1) to show if anisomysin induces delayed cardioprotective effect in mouse heart following ischemia/reperfusion; (2) to demonstrate if the late preconditioning effect is mediated by p38 phosphorylation and activation of transcription factor NF-B; (3) to determine the role of p38 activation in the expression of iNOS, synthesis of nitric oxide (NO) and to provide their cause and effect in delayed cardioprotection. Our results suggest that targeted phosphorylation of p38 with anisomycin leads to the delayed cardioprotective effect, which is mediated by NF-B activation and synthesis of iNOS. Also, the anisomycin-induced delayed cardioprotection is absent in mice with targeted ablation of iNOS gene.
Materials and Methods

Animals
Adult male out-bred mice (ICR Strain, 30 to 40 g) were supplied by Harlan (Indianapolis, Ind). Adult males with targeted disruption of iNOS gene (Ϫ/Ϫ) B6.129 and B6.129 wild-type mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) The care and use of animals were conducted in accordance with the guidelines of the Committee on Animals of Virginia Commonwealth University and the National Institutes of Health (DHHS publication No. 80-23, revised).
Chemicals and Supplies
Anisomycin was obtained from RBI; SB203580 and PD98059 were obtained from Calbiochem; gel electrophoresis supplies were obtained from BioRad Laboratories; pyrrolidinediethyldithiocarbamate (PDTC) and all other chemicals were obtained from Sigma Chemical. The antibodies for Western blotting were obtained from the following companies: phospho-specific p38 MAPK (Thr 180/Tyr 182), New England Biolabs; and p38, iNOS, p50, p65, and rabbit polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, Calif).
Langendorff's Isolated Heart Perfusion
The methodology of Langendorff's isolated perfused mouse heart preparation and measurement of contractile function have been described previously in detail. 20, 23, 30 Transverse slices of the heart were stained in 10% TTC for 30 minutes followed by measurement of the infracted areas using computer morphometry as described previously. 20, 21, 23 The infarct size was measured after 30 minutes of reperfusion, which is sufficient for accurate detection of infarct size as described by Schaper et al. 31 
Experimental protocol
Cardiac Function and Infarct Studies
Mice were randomized into 12 groups and received the following drugs intraperitoneal 24 hours before sacrifice. 
p38 Phosphorylation
A subset of animals were treated with anisomycin, and 10, 15, and 30 minutes later, the hearts were removed for measurement of p38 phosphrylation.
NF-B Binding Activity
To determine the time course of NF-B binding activity, another set of mice were treated with either DMSO or anisomycin, and 15, 30, 60, and 120 minutes later, left ventricular (LV) samples were harvested and stored frozen at Ϫ70°C until analyzed for NF-B by electrophoretic mobility shift assay (EMSA). Another subset of mice was treated with drugs as described in Group 1 to 6. The tissue samples were collected 30 minutes later for measurement of NF-B binding activity. These mice were not subjected to ischemia/reperfusion protocol.
Expression of iNOS and NO Synthesis
Mice were treated with anisomycin, and 6, 10, 16, and 24 hours later, LV tissue was harvested and frozen in liquid nitrogen for measurement of iNOS mRNA by RT-PCR. Another subset of mice (nϭ3 to 4) was treated as described in Group 1 to 6, and LV tissue was collected 24 hours later to measure iNOS protein and NO.
Western Blot Analysis
Frozen tissue samples were ground in liquid nitrogen and lysed in the Tris buffer (pH 7.9) containing 140 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 1 mmol/L EGTA, 1 mmol/L EDTA, 1 mmol/L DTT, 0.5% NP-40, 0.5 mmol/L sodium orthovanadate, and protease inhibitors (0.5 mmol/L phenylmethylsulfonyl fluoride, 1 g/mL aprotinin, and 1 g/mL leupeptin). The samples were homogenized using a Polytron (Brinkman) and microcentrifuged at 14 000 rpm for 10 minutes. The protein content of the supernatant was determined using the DC-protein assay (BioRad). Western blots were performed as per the manufacturer's instructions (Cell Signaling Technology). The protein was separated by SDS-PAGE using 12% SDS for p38, 10% SDS for p50, and p65 NF-B proteins or 8% SDS for iNOS protein. The gels were incubated with the respective primary antibody, washed, and visualized by incubation with anti-rabbit horseradish peroxidase-conjugated secondary antibody BioRad (Hercules, Calif) and ECL Chemiluminescence Detection Reagent from Amersham Pharmacia Biotech.
Electrophoretic Mobility Shift Assay
Preparation of nuclear extract and EMSA were performed according to the method of Taher et al. 32 A double-stranded 22-mer oligonucleotide with the sequence 5Ј-AGTTGAGGGGACTTTAGGC-3Ј (Promega Corp) was end-labeled using [␥-32 p] ATP (ICN) and T4 polynucleotide kinase according to the manufacturer's instructions. To ensure the specificity of NF-B, gel competition assay was performed by incubating nuclear extracts with 50-and 100-fold molar excess of unlabeled (cold) doubled-stranded NF-B before addition of [ 32 p]-labeled NF-B oligonucleotide.
RT-PCR of iNOS
Total cellular RNA was isolated from LV tissue with Trizol reagent (Gibco BRL, Life Technologies). RNA (5 g) was reverse tran-scribed to generate cDNA using standard methodology. The reversetranscribed cDNA (10 L) was amplified in a final volume of 100 L by PCR under standard conditions (1.5 mmol/L MgCl 2 , 200 mol/L dNTP, and 4.0 U Taq polymerase) with 50 mol/L of primers for iNOS based on the sequence for murine iNOS cDNA. The primers were synthesized with the following sequences: iNOS, up: 5Ј-TGTCGCAGCTCCCTATCTTG-3Ј; down: 5Ј-CATTG-GCCAGCTGCTTTTGC-3Ј. The experimental conditions for PCR were 30 cycles for 60 seconds at 94°C, 55°C, and 72°C. After amplification, 10 L of PCR product per lane was resolved on 1.5% agarose gel containing ethidium bromide in 1ϫ TBA buffer. Bands were confirmed under UV fluorescence and purified by using a Qiagen purification kit. The nucleotide sequences for iNOS was determined by the same up primer used for PCR reaction and a DNA sequencer. The reproducibility of iNOS RT-PCR was confirmed by at least 2 samples in each group.
Measurement of NO
NO was measured with a Sievers nitric oxide analyzer (model 280), as described previously. 20 Briefly, hearts were collected, powdered under liquid nitrogen, and homogenized at 4°C with a Polytron PT 20 (4 bursts of 5 seconds each) in 5 volumes of PBS (pH 7.4). They were then centrifuged at 14 000 rpm for 10 minutes and the pellets discarded. Samples were deproteinized with 200°proof ethyl alcohol at 0°C in a 1:2 v/v mix and incubated 30 minutes at 0°C followed by centrifugation at 14 000 rpm for 5 minutes. The pellets were discarded and the supernatant was used to measure inactivated NO in the form of nitrate, nitrite, and S-nitrosocompounds by reducing these to NO with vanadium (III)-HCl. NO was then measured based on a gas-phase chemiluminescent reaction between NO and ozone with a NOA 280 (Sievers Instruments).
Statistical Analysis
The results are expressed as the meanϮSEM. Difference among the groups were analyzed by one-way analysis of variance (ANOVA). Statistical differences were considered significant with a value of PϽ0.05.
Results
Infarct Size
Myocardial infarct size was 30.9Ϯ2.4% in the vehicle-treated hearts, which was reduced to 10.9Ϯ3.4% after treatment with anisomycin (PϽ0.05, Figure 1 ). SB303580, the inhibitor of p38, abolished the protective effect of anisomycin as indicated by increase in the infarct size to 30.0Ϯ3.1% (PϽ0.05). The infarct size in SB203580-treated mice was 28.3Ϯ2.6%, which was not different from the vehicle group (PϾ0.05). However, PD 98059, the inhibitor of ERK, failed to block the infarct limiting effect of anisomycin, ie, 13.8Ϯ2.9% versus 10.9Ϯ3.4% with anisomycin (PϾ0.05). Also, PD 98059 had no effect on infarct size in the control hearts that were not pretreated with anisomycin (infarct size: 29.0Ϯ1.4% versus 30.9Ϯ2.4% in the vehicle group). PDTC, a potent inhibitor of NF-B, blocked the infarct limiting effect of anisomycin while having no effect in the control hearts, ie, 25.9Ϯ2.7% versus 30.9Ϯ2.4% in the vehicle control group. SMT, a selective iNOS inhibitor, when administrated 30 minutes before ischemia and reperfusion blocked the protective effect of anisomycin as indicated by increase in infarct size to 23.8Ϯ3.6%. The infarct size in SMT-treated control mice was 26.0Ϯ4.0% that was also not different compared with the SMTϩanisomycin or vehicle treated control group. Treatment of iNOS gene knockout mice with anisomycin failed to reduce infarct size (25.2Ϯ4.4% versus 30.9Ϯ2.4% in the vehicle group, PϾ0.05). However, treatment of B6.129 wild-type strain of mice with anisomycin still exhibited a reduction in the infarct size (8.7Ϯ2.4% versus 30.9Ϯ2.4% in the vehicle group, Figure 1 ). LVSP indicates left ventricular systolic pressure; LVEDP, left ventricular diastolic pressure; HR, heart rate; and CF, coronary flow. Refer to Figure 1 legend for group abbreviations.
Preischemic Baseline Hemodynamic Data
Ventricular Function
Myocardial functional parameters LVSP, LVEDP, heart rate, and coronary flow were not significantly different between groups during preischemia (Table) . Postischemic LVEDP improved in the anisomysin-treated group (4.4Ϯ1.4 mm Hg) as compared with the vehicle group (25.0Ϯ3.6 mm Hg, PϽ0.05, Figure 2A ). Anisomycin-induced improvement in LVEDP was abolished by SB203580 (30.1Ϯ3.1 mm Hg), PDTC (21.3Ϯ4.5 mm Hg, PϽ0.05), and SMT (17.4Ϯ 2.9 mm Hg, PϽ0.05), but not by PD98059 (3.7Ϯ1.5 mm Hg, PϾ0.05). LVEDP was elevated in iNOS knockout mice (21.8Ϯ4.7 mm Hg) as compared with B6.129 wild-type strain mice (3.0Ϯ2.1 mm Hg, PϽ0.05). The recovery of postischemic LVDP was 57.2Ϯ7.1 mm Hg in the vehicle group, which increased to 75.2Ϯ3.4 mm Hg in the anisomycin group (PϾ0.05, Figure 2B ). LVDP was 61.8Ϯ5.8, 66.0Ϯ8.7, and 55.7Ϯ11.5 mm Hg in the SB203580, PDTC, and SMT groups, respectively (PϾ0.05 versus anisomycin treated group). Anisomycin induced improvement of LVDP was not blocked by PD98059 (84.0Ϯ5.4 mm Hg). Postischemic recovery of LVDP in the iNOS gene knockout mice was lower as compared with B6.129 wild-type mice (50.1Ϯ9.7 versus 70.0Ϯ3.2 mm Hg) after anisomycin treatment. An identical trend in the changes in the recoveries of rate pressure product ( Figure 2C ) was observed. Postischemic recoveries of heart rate and coronary flow were similar in all the groups (not shown).
p38 Phosphrylation
Phosphrylated p38 was present at low levels in the vehicletreated mice. A mild increase in phosphrylated p38 was detected 10 minutes after treatment with anisomycin, which reached maximum level at 15 minutes and declined by 30 minutes ( Figure 3A ). Quantitative analysis showed that anisomycin elicited a 4-fold increase in p38 phosphorylation at 15 minutes after treatment. Total p38 expression remained unaltered ( Figure 3B ).
NF-B Binding Activity
NF-B binding activity was low or undetectable in vehicletreated mice. Administration of anisomycin resulted in a rapid increase in NF-B binding activity at 15 minutes, which peaked at 30 minutes ( Figure 4A ). Quantitative analysis showed that NF-B binding activity increased 4.3-fold at 30 minutes (PϽ0.05 versus control) and returned to values not significantly different from control group after 2 hours of treatment ( Figure 4B ). Western blot showed accumulation of NF-B p50 and p65 protein in nuclear extract after anisomycin treatment ( Figure 4C ). The anisomycin-induced increase in NF-B binding activity was attenuated by pretreatment with SB203580 and PDTC ( Figure 5A ). SB203580 and PDTC had no effect on NF-B binding activity ( Figure 5A and 5B). Incubation of nuclear extracts with 50-fold molar excess of cold oligonucleotide inhibited formation of the NF-B/DNA complex after anisomycin treatment confirming the specificity of binding ( Figure 5C ).
Expression of iNOS and Synthesis of NO
Enhanced RT-PCR product of the predicted size (492 bp) was identified beginning at 6 hours, which remained elevated up to 24 hours after anisomycin administration ( Figure 6 ). The RT-PCR product showed 100% homology with murine macrophage iNOS sequence. iNOS protein was observed in vehicle group, which was significantly elevated by 24 hours after anisomycin treatment ( Figure 7A ). Densitometric analysis showed a 2.1-fold increase in iNOS protein at 24 hours after anisomycin treatment as compared with control (PϽ0.05), which decreased with SB203580 and PDTC. SB203580 and PDTC had little effect on iNOS protein ( Figure 7B ). Furthermore, pretreatment with anisomycin caused increase in NO levels 24 hours later compared with vehicle group (8.0Ϯ1.0 versus 4.9Ϯ0.9 nmol/mg · protein, PϽ0.05, Figure 7C ), which was significantly decreased by SB203580 (2.80Ϯ0.07 nmol/mg · protein) and PDTC (2.4Ϯ0.3 nmol/mg · protein).
Discussion
Our results show that selective activation of p38 with anisomycin triggered delayed cardioprotection in the heart, as indicated by reduction in infarct size and significant improvement of postischemic LVEDP after global ischemia and reperfusion. In addition, these results provide direct evidence for the causative role of p38 in triggering downstream signaling involving activation of NF-B, expression of iNOS, and increased synthesis of NO leading to delayed cardioprotection.
The role of p38 signaling in acute IPC has been extensively investigated, although conflicting results have been obtained. 5 Maulik et al 6 suggested the involvement of tyrosine kinase-phospholipase D as a potential signaling pathway in IPC. Weinbrener et al 4 showed an increase of p38 phosphorylation in the preconditioned heart that was blocked by adenosine receptor antagonist. Sakamoto et al 33 also demonstrated partial blockade of the cardioprotective effect of CCPA with SB203580 in the isolated perfused rat heart. A transient dual phosphorylation and activation of p38 occurred during preconditioning, 34 which was attenuated during sustained ischemia/reperfusion and was associated with improved functional recovery. In contrast, SB203580 decreased myocardial apoptosis, 35 improved postischemic cardiac function, 36 and decreased LDH release in myocytes after ischemia. 9 The role of p38 in late preconditioning has been described after pharmacological activation of adenosine A 1 receptor. Increased expression of phospho-specific p38 was observed 24 hours after stimulation with A 1 receptor in the rabbit and mouse hearts, which was blocked by genistein 11 and SB203580. 12 These studies suggested that p38 pathway as a potential distal effector of late preconditioning. In the present studies, administration of SB203580 before anisomycin abolished the protection suggesting that p38 acts as a trigger of delayed protection. It is not clear which specific isoform(s) of p38, ie, ␣, ␤, ␥, or ␦ are phosphorylated with anisomycin in the present studies. However, it is well known that SB 203580 is a potent inhibitor of p38␣ and ␤, but has little effect on ␥ and ␦. 37 Thus, based on our data on blockade of anisomycin-induced delayed cardioprotection with SB 203580, it appears that p38␣ and ␤ isoforms may be involved. Further studies are needed to resolve the isoformselective effects of anisomycin. The role of SAPK/JNK, however, remains speculative, because so far no specific antagonist for this kinase has been developed. Previous studies have shown that anisomycin causes a low level dual-phosphorylation of p44/42 MAP kinase in HepG2 cells. 38 However, pretreatment of mice with PD98059, a specific inhibitor for MEK1 or 2, the upstream activator of p42/44 MAP kinase, 39 failed to abolish anisomycin-mediated delayed cardioprotection. In contrast, both p44/42 MAP kinase and p38 have been suggested to be integral components of delayed pharmacological preconditioning induced by activation of opioid receptor and were proposed to be acting via parallel pathways. 40 In the present studies, we observed a rapid transient increase in NF-B DNA binding activity within 30 minutes after treatment with anisomycin, which was attenuated by 2 hours. SB203580 and PDTC, the specific inhibitor of NF-B, 41 not only blocked the DNA binding but also abolished the delayed cardioprotection. It has been suggested that p38 signals through the transcription factor NF-B. 18, 42 NF-B exists in the cytoplasm of many cells complexed to an inhibitor, IB. Treatment of cells with TNF-␣, IL-1, and LPS leads to phosphorylation and proteolytic degradation of IB and release of NF-B, which then translocates to the nucleus and binds its cognate DNA sequence on responsive genes. NF-B activation has also reported to be essential for the development of delayed PC in vivo. 19 Our results show that peak p38 phosphorylation preceded the maximum NF-B activation after anisomycin treatment suggesting the possibility that NF-B is the downstream target of p38 in the signaling cascade. The mechanism by which stimulation of p38 increases NF-B DNA binding is not clear. It is likely that p38 increased NF-B binding activity by phosphorylation of its inhibitor IB or indirectly via intermediate kinases. 18, 43 Our results also demonstrated that anisomycin caused rapid transcription of iNOS mRNA, which peaked by 6 to 24 hours later. Additionally, anisomycin caused increased transcription of iNOS gene and NO synthesis 24 hours later, which was attenuated by SB203580, suggesting the role of p38 activation in regulating iNOS expression. Similarly, anisomycin was shown to increase mRNA levels, iNOS activity, and protein in rat aortic smooth muscle cells. 44 Although anisomycin is a protein synthesis inhibitor, it can efficiently activate transcription of certain genes, including either the iNOS or the c-fos. 45 Anisomycin-induced iNOS protein synthesis was dependent on activation of NF-B because pretreatment with PDTC attenuated the increase in iNOS protein and NO levels.
Finally, we observed that inhibition of iNOS or targeted ablation of this gene in mice resulted in abrogation of anisomycin-induced delayed cardioprotection, suggesting an essential role of NO in p38-triggered protection. It is likely that NO is a mediator in this protective effect because SMT was administered 24 hours after anisomycin treatment. Previous studies have shown that NO is the possible trigger as well as the mediator for PC 46 because administration of a NO-synthase inhibitor L-nitroarginine and aminoguanidine abolished the delayed PC against myocardial stunning and infarction. 24, 25 We have shown that NO plays a prominent role both in mediating this delayed cardioprotective response induced by adenosine A 1 /A 3 receptor activation, 23, 47 mitoK ATP channel opener, diazoxide, 48 and monophosphoryl lipid A or its synthetic analogue, RC522. 20, 21 These studies also showed an absence of delayed protection in the iNOS knockout homozygous mutant mice. Therefore, it appears that there is significant redundancy in the signaling pathways induced either by direct pharmacological treatment or stress (IPC) in the heart.
In conclusion, we have provided evidence that targeted activation of p38 by anisomycin triggers downstream signaling pathway leading to the rapid transient activation of NF-B, transcription and synthesis of iNOS, as well as NO leading to the development of long-lasting cardioprotective effect. These effects of p38 activation were observed in the absence of confounding effects of activation of membrane receptors and ensuing signaling cascade. The selective inhibition of either the trigger, ie, p38 or the mediators (NF-B or iNOS) resulted in the abrogation of delayed cardioprotective effect. In addition, the absence of delayed cardioprotective response in the iNOS gene-knockout mice further provides genetic evidence of the essential role of iNOS in this signaling cascade. We propose that novel drugs/therapies could be developed based on targeted transient activation of p38 that may lead to late preconditioning effect in the ischemic heart.
